Skip to content

Clinical trials

Observational Lung Diseases, Interstitial trials

Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.

Filters: Condition: Lung Diseases, Interstitial Phase: Observational Clear all

270 trials match Source: ClinicalTrials.gov registrations

Trials started per year

By phase, 2000 to 2026.

Trials started per year
CategoryTrials
20001
20011
20031
20054
20064
20074
20084
20094
20106
20115
20128
201310
20148
20157
201611
201715
201812
201911
202022
202121
202219
202327
202420
202520
202618

Status

Trials by registry status. Select a bar to filter.

Trials by status
CategoryTrials
Completed104
Unknown status63
Recruiting58
Not yet recruiting16
Active, not recruiting11
Terminated9
Enrolling by invitation6
Withdrawn2
Suspended1

Top lead sponsors

A sponsor with a page on Pharma Observatory links to it.

Top lead sponsors
CategoryTrials
Assiut University13
Boehringer Ingelheim10
Central Hospital, Nancy, France5
Celgene4
Columbia University4
Hospices Civils de Lyon4
National Heart, Lung, and Blood Institute (NHLBI)4
National Jewish Health4
Singapore General Hospital4
Assistance Publique - Hôpitaux de Paris3

Top conditions

MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.

Top conditions
CategoryTrials
Lung Diseases, Interstitial270
Idiopathic Pulmonary Fibrosis50
Pulmonary Fibrosis38
Pulmonary Disease, Chronic Obstructive36
Arthritis, Rheumatoid23
Asthma21
Lung Diseases18
Lung Neoplasms16
Sarcoidosis15
Scleroderma, Systemic14

Trials

Showing 76 to 100 of 270. Each trial links to its page on Pharma Observatory.

170 more trials match. See them on Pharma Observatory

Recently changed trials

Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.

No changes to these trials in the last 7 days.

Go deeper on Pharma Observatory

Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.